AstraZeneca becomes Britain’s first £200bn company

AstraZeneca has become Britain’s first £200bn company following a 20pc rally in its share price since the start of the year.Shares in the pharmaceutical business rose 1.1pc yesterday to value the company at £200.3bn.]]&gt…

About Author

Chris Price

See author's posts

AstraZeneca becomes Britain’s first £200bn company

About Author

Chris Price

Experts Debate Whether IRA Provisions Stifle Pharma Innovation at Senate Hearing

Fidson healthcare signs deal with 3 Chinese firms to build pharmaceutical plant Lekki FTZ

California May Regulate and Restrict Pharmaceutical Brokers

Oncologica to advance urine-based prostate cancer screening test

Not just a normal part of aging: Dizziness in older adults is linked to higher risk of future falls

FDA Approves Benralizumab for EGPA Vasculitis Indication

Study finds early puberty linked to higher risk for HS

CGM Cuts Hospitalization in T2D, Even in Non-Insulin Treated

Budget FY25: Pharmaceuticals sector needs a major boost with increased focus on R&D and innovation

Dental veneers: Everything you need to know

Cheeky diet soft drink getting you through the work day? Here’s what that may mean for your health

UK teenagers get two-thirds of their calories from ultra-processed foods—new study

Some have called this area a birthing ‘desert.’ A nurse midwife is working to change that

Oncologica to advance urine-based prostate cancer screening test

Not just a normal part of aging: Dizziness in older adults is linked to higher risk of future falls

FDA Approves Benralizumab for EGPA Vasculitis Indication

Study finds early puberty linked to higher risk for HS

CGM Cuts Hospitalization in T2D, Even in Non-Insulin Treated

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories